Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Karuna Therapeutics
Pharma
BMS wins FDA approval for new schizophrenia med Cobenfy
Bristol Myers Squibb’s $14 billion deal for Karuna Therapeutics has borne fruit with the approval of a promising new schizophrenia drug.
Fraiser Kansteiner
Sep 26, 2024 7:38pm
BMS' dealmaking appetite remains intact, CEO says
Jun 12, 2024 10:55am
Alkermes reports strong trajectory for Lybalvi, shares up 10%
Feb 15, 2024 1:10pm
‘The Top Line’: The most anticipated drug launches of 2024
Feb 9, 2024 6:00am
JPM24: BMS CEO Boerner focuses on pipeline—even after M&A deals
Jan 8, 2024 2:06pm
Alnylam, Intra-Cellular among RBC's top picks for M&A
Apr 19, 2023 3:20pm
